By: Stefania Pierce
The Bidirectional Relationship Between Epilepsy and Depression
Introduction
Depression is one of the most common conditions faced by individuals living with epilepsy. Research has consistently shown that people with epilepsy are more likely to develop depressive disorders than both the general population and other individuals with chronic health conditions. It has also been shown that the reverse is true in that individuals who experience depression have a three- to seven-times higher risk of later developing epilepsy (Forsgren & Nystrom, 1999; Hesdorffer et al., 2000, 2006). This two-way relationship suggests that depression and epilepsy are closely connected, rather than existing as completely separate conditions. Instead of one simply causing the other, researchers believe that both disorders may arise from shared underlying biological and neurological mechanisms (Kanner, 2009).
Depressive episodes have shown to be the most common comorbidity associated with this condition, affecting between 11% and 62% of patients (Blaszczyk & Czuczwar, 2016). These symptoms can significantly impact daily functioning, treatment adherence, and overall quality of life. Despite this, depression in individuals with epilepsy is often underrecognized and undertreated. Understanding the shared pathways between these two conditions is therefore essential, not only for improving clinical care but also for developing more effective, integrated treatment approaches. By examining the biological, psychological, and environmental factors that link epilepsy and depression, this paper aims to highlight the importance of addressing mental health as a central component of epilepsy management.
Evidence from Animal Models
Animal models have played a critical role in helping researchers better understand the biological connection between epilepsy and depression. Studies using genetically modified and naturally occurring epilepsy-prone rats provide important insight into how mood-related symptoms may develop alongside seizure disorders. For example, one study showed that Genetic Absence Epilepsy Rats (rats who develop epilepsy with no prior genetic markers for the condition) not only experience spontaneous seizures, but also display behaviors associated with anxiety and depression. The most important finding of this study is that these rats exhibit increased depressive and anxious behaviors even before the onset of visible seizure activity, suggesting that emotional difficulties are not simply a reaction to living with epilepsy, but may develop simultaneously as part of the disorder itself (Jones et al., 2008). Genetically epilepsy-prone rats also demonstrate depressive-like behaviors that can be linked to disruptions in key neurotransmitter systems (particularly serotonin and norepinephrine). These disruptions appear to result from impaired development of the nerve cells responsible for producing these chemicals, highlighting a shared neurobiological basis for both mood regulation and seizure activity (Jobe et al., 1994).
Animal models have also demonstrated that environmental factors play an important role. Research has shown that early life stress, such as maternal separation in female rats, increases susceptibility to epilepsy-like seizures later in life, emphasizing how stress and early experiences can interact with biological risk factors (Salzberg et al., 2007; Jones et al., 2009). Together, findings from animal research not only demonstrate that epilepsy and depression share genetic and environmental risk factors but also point toward specific biological mechanisms that may underlie this relationship. In particular, many of the behavioral changes observed in epilepsy-prone animals appear to be linked to disruptions in key neurotransmitter systems. These results provide an important foundation for examining how similar neurochemical imbalances operate in humans, where advances in brain imaging and clinical studies have further clarified the role of neurotransmitters in shaping both seizure activity and mood regulation.
Neurochemical and Neurological Disfunctions
Neurochemical systems, particularly those involving serotonin and glutamate, appear to play a critical role in the link between epilepsy and depression. Brain imaging studies in humans suggest that disruptions in serotonin activity are associated with both seizure disorders and depressive symptoms, indicating that this neurotransmitter may contribute to the development and progression of both conditions (Sargent et al., 2000; Toczek et al., 2003; Theodore et al., 2006; Hasler et al., 2007). Further supporting this connection, treatment with selective serotonin reuptake inhibitors or SSRIs (which work by upregulating serotonin in the brain) has been shown to significantly reduce seizure frequency in patients with treatment-resistant epilepsy, highlighting serotonin’s important role in seizure regulation as well as mood stabilization (Favale et al., 1995, 2003; Specchio et al., 2004).
Alongside serotonin dysfunction, abnormalities in glutamate regulation also appear to contribute to the comorbidity between epilepsy and depression. Glutamate is the brain’s primary excitatory neurotransmitter, and its levels must be carefully controlled to maintain healthy neural activity. Research indicates that individuals with both depression and epilepsy often exhibit reduced levels of glutamate transporters, particularly in key brain regions involved in mood and cognition (Choudary et al., 2005; McCullumsmith & Meador-Woodruff, 2002). This reduction may lead to excessive glutamate accumulation, increasing neuronal excitability and potentially causing neural damage over time. Together, disruptions in serotonin and glutamate systems provide strong evidence that shared neurochemical imbalances underlie both depressive symptoms and seizure vulnerability, further reinforcing the close biological relationship between these conditions.
Stress, HPA Axis Dysfunction, and Corticosteroids
While disruptions in serotonin and glutamate systems highlight the importance of neurochemical imbalance in linking epilepsy and depression, these processes do not operate in isolation. Neurotransmitter functioning is closely influenced by the body’s stress response systems, suggesting that broader regulatory networks may also contribute to this comorbidity. In particular, growing evidence points to dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis as another key biological pathway through which mood and seizure vulnerability become interconnected. One of the earliest biological markers identified for major depressive disorder is an abnormal response on the dexamethasone suppression test (a measure of how effectively the body regulates stress hormones). Interestingly, this same abnormal pattern has been observed in individuals with temporal lobe epilepsy as well as in animal models of epilepsy, suggesting overlapping stress-related dysfunction across both conditions (Zobel et al., 2004; Mazarati et al., 2009). Even in the absence of clinical depression, people with temporal lobe epilepsy often exhibit an overactive HPA axis, resembling the heightened stress response commonly seen in individuals with mood disorders (Zobel et al., 2004). These findings indicate that chronic stress and impaired hormonal regulation may be fundamental features of epilepsy rather than simply secondary consequences.
Corticosteroids, which are key hormones released during stress, appear to further contribute to both emotional and neurological vulnerability. Excessive corticosteroid activity has been linked to reductions in serotonin receptor availability, potentially weakening the brain’s ability to regulate mood and seizure activity (Zobel et al., 2004). In animal studies, rats with epilepsy who exhibit elevated corticosteroid levels between seizures also show more severe depressive-like symptoms, highlighting the emotional consequences of prolonged stress exposure (Mazarati et al., 2009). In addition, experimental administration of corticosteroids to healthy female rats has been shown to accelerate the development of seizures, demonstrating a direct link between stress hormones and seizure susceptibility (Kumar et al., 2007). Together, these findings suggest that chronic activation of the stress response system may act as a shared biological pathway that increases the risk for both depression and epilepsy, reinforcing the importance of stress regulation in clinical management and treatment.
Conclusion
Overall, evidence from human studies, animal models, neuroimaging research, and pharmacological investigations strongly suggests that epilepsy and depression share common underlying biological mechanisms involving neurotransmitter systems and stress regulation. Findings related to serotonin and glutamate dysfunction, HPA axis dysregulation, and elevated corticosteroid activity demonstrate that both conditions are influenced by overlapping neurochemical and hormonal pathways. In addition, results from animal models highlight the combined impact of genetic vulnerability and early life stress in shaping long-term emotional and neurological outcomes. Together, these shared pathways help explain the high prevalence and bidirectional nature of depression in individuals with epilepsy. Rather than representing separate or secondary conditions, depression and epilepsy appear to be interconnected disorders that emerge from common biological and environmental influences. Recognizing this close relationship is essential for improving early identification, prevention, and treatment strategies. Integrated approaches that address both seizure control and mental health may lead to better clinical outcomes, enhanced quality of life, and more comprehensive care for individuals living with epilepsy.
Resources
Błaszczyk, B., & Czuczwar, S. J. (2016). Epilepsy coexisting with depression. Pharmacological Reports, 68(5), 1084–1092. https://doi.org/10.1016/j.pharep.2016.06.011
Choudary, P. V., Molnar, M., Evans, S. J., Tomita, H., Li, J. Z., Vawter, M. P., Myers, R. M., Bunney, W. E., Jr., Akil, H., Watson, S. J., & Jones, E. G. (2005). Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proceedings of the National Academy of Sciences of the United States of America, 102(43), 15653–15658. https://doi.org/10.1073/pnas.0507901102
Favale, E., Audenino, D., Cocito, L., & Albano, C. (2003). The anticonvulsant effect of citalopram is indirect evidence of serotonergic impairment in human epileptogenesis. Seizure, 12(5), 316–318. https://doi.org/10.1016/S1059-1311(02)00296-6
Favale, E., Rubino, V., Mainardi, P., Lunardi, G., & Albano, C. (1995). The anticonvulsant effect of fluoxetine in humans. Neurology, 45(10), 1926–1927. https://doi.org/10.1212/WNL.45.10.1926
Forsgren, L., & Nyström, L. (1999). An incident case-referent study of epileptic seizures in adults. Epilepsy Research, 6(1), 66–81.
Hasler, G., Bonwetsch, R., Giovacchini, G., Toczek, M. T., Bagic, A., Luckenbaugh, D. A., Drevets, W. C., & Theodore, W. H. (2007). 5-HT₁A receptor binding in temporal lobe epilepsy patients with and without major depression. Biological Psychiatry, 62(11), 1258–1264. https://doi.org/10.1016/j.biopsych.2007.04.027
Hesdorffer, D. C., Hauser, W. A., Annegers, J. F., & Cascino, G. (2000). Major depression is a risk factor for seizures in older adults. Annals of Neurology, 47(2), 246–249. https://doi.org/10.1002/1531-8249(200002)47:2<246::AID-ANA16>3.0.CO;2-E
Hesdorffer, D. C., Hauser, W. A., Olafsson, E., Ludvigsson, P., & Kjartansson, O. (2006). Depression and suicide attempt as risk factors for incident unprovoked seizures. Annals of Neurology, 59(1), 35–41. https://doi.org/10.1002/ana.20685
Jobe, P. C., Mishra, P. K., Browning, R. A., Wang, C., Adams-Curtis, L. E., Ko, K. H., & Dailey, J. W. (1994). Noradrenergic abnormalities in the genetically epilepsy-prone rat. Brain Research Bulletin, 35(5–6), 493–504. https://doi.org/10.1016/0361-9230(94)90139-2
Jones, N. C., Kumar, G., O’Brien, T. J., Morris, M. J., Rees, S. M., & Salzberg, M. R. (2009). Anxiolytic effects of rapid amygdala kindling and the influence of early life experience in rats. Behavioural Brain Research, 203(1), 81–87. https://doi.org/10.1016/j.bbr.2009.04.021
Jones, N. C., Salzberg, M. R., Kumar, G., Couper, A., Morris, M. J., & O’Brien, T. J. (2008). Elevated anxiety and depressive-like behavior in a rat model of genetic generalized epilepsy, suggesting common causation. Experimental Neurology, 209(1), 254–260. https://doi.org/10.1016/j.expneurol.2007.10.012
Kanner, A. M. (2009). Depression and epilepsy: A review of multiple facets of their close relation. Neurologic Clinics, 27(4), 865–880. https://doi.org/10.1016/j.ncl.2009.06.001
Kumar, G., Couper, A., O’Brien, T. J., Salzberg, M. R., Jones, N. C., Rees, S. M., & Morris, M. J. (2007). The acceleration of amygdala kindling epileptogenesis by chronic low-dose corticosterone involves both mineralocorticoid and glucocorticoid receptors. Psychoneuroendocrinology, 32(7), 834–842. https://doi.org/10.1016/j.psyneuen.2007.06.0040
Mazarati, A. M., Shin, D., Kwon, Y. S., Bragin, A., Pineda, E., Tio, D., Taylor, A. N., & Sankar, R. (2009). Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiology of Disease, 34(3), 457–461. https://doi.org/10.1016/j.nbd.2009.02.016
McCullumsmith, R. E., & Meador-Woodruff, J. H. (2002). Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology, 26(3), 368–375. https://doi.org/10.1016/S0893-133X(01)00349-0
Salzberg, M., Kumar, G., Supit, L., Jones, N. C., Morris, M. J., Rees, S., & O’Brien, T. J. (2007). Early postnatal stress confers enduring vulnerability to limbic epileptogenesis. Epilepsia, 48(11), 2079–2085. https://doi.org/10.1111/j.1528-1167.2007.01208.x
Sargent, P. A., Kjaer, K. H., Bench, C. J., Rabiner, E. A., Messa, C., Meyer, J., Gunn, R. N., Grasby, P. M., & Cowen, P. J. (2000). Brain serotonin 1A receptor binding measured by positron emission tomography with [¹¹C]WAY-100635: Effects of depression and antidepressant treatment. Archives of General Psychiatry, 57(2), 174–180. https://doi.org/10.1001/archpsyc.57.2.174
Specchio, L. M., Iudice, A., Specchio, N., La Neve, A., Spinelli, A., Galli, R., Rocchi, R., Ulivelli, M., De Tommaso, M., Pizzanelli, C., & Murri, L. (2004). Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology, 27(3), 133–136. https://doi.org/10.1097/00002826-200405000-00004
Theodore, W. H., Giovacchini, G., Bonwetsch, R., Bagic, A., Reeves-Tyer, P., Herscovitch, P., & Carson, R. E. (2006). The effect of antiepileptic drugs on 5-HT receptor binding measured by positron emission tomography. Epilepsia, 47(3), 499–503. https://doi.org/10.1111/j.1528-1167.2006.00451.x
Toczek, M. T., Carson, R. E., Lang, L., Ma, Y., Spanaki, M. V., Der, M. G., Fazilat, S., Kopylev, L., Herscovitch, P., Eckelman, W. C., & Theodore, W. H. (2003). PET imaging of 5-HT₁A receptor binding in patients with temporal lobe epilepsy. Neurology, 60(5), 749–756. https://doi.org/10.1212/01.WNL.0000052995.87334.07
Zobel, A., Wellmer, J., Schulze-Rauschenbach, S., Pfeiffer, U., Schnell, S., Elger, C., & Maier, W. (2004). Impairment of inhibitory control of the hypothalamic–pituitary–adrenocortical system in epilepsy. European Archives of Psychiatry and Clinical Neuroscience, 254(5), 303–311. https://doi.org/10.1007/s00406-004-0518-8
